10-Q: Astrotech Corporation Reports First Quarter Fiscal Year 2025 Results

Astrotech Corporation reported a net loss of $3.3 million for the quarter ended September 30, 2024, with revenue of $34 thousand.

Summary

• Astrotech Corporation reported a net loss of $3.3 million for the quarter ended September 30, 2024, compared to a net loss of $2.9 million for the same period in 2023.
• Revenue for the quarter was $34 thousand, a significant decrease from $425 thousand in the prior year's quarter.
• The company's gross profit was $9 thousand, down from $183 thousand in the same quarter of the previous year.
• Operating expenses totaled $3.6 million, slightly up from $3.5 million in the prior year.
• Cash and cash equivalents decreased to $6.5 million from $10.4 million at the end of the previous quarter.
• The company's working capital was approximately $29.5 million as of September 30, 2024.
• Astrotech has 1,701,729 common shares outstanding as of November 8, 2024.

Sentiment

Score: 3

Explanation: The document indicates a significant decrease in revenue and an increase in net loss, which is concerning. However, there are some positive developments in product development and partnerships. Overall, the sentiment is negative due to the poor financial results.

Positives

• The TRACER 1000 has been approved by the TSA for the Air Cargo Security Technology List, advancing it to Stage II testing.
• AgLAB's field trials indicate the AgLAB 1000-D2 can improve yields of THC and CBD oil during distillation by 20% or more.
• AgLAB has partnered with SC Laboratories to market the AgLAB 1000-D2.
• The company has deployed its TRACER 1000 devices in approximately 30 locations across 14 countries.

Negatives

• The company's revenue decreased significantly to $34 thousand in the first quarter of fiscal year 2025.
• Astrotech experienced a net loss of $3.3 million for the quarter.
• Gross profit declined substantially to $9 thousand.
• Cash and cash equivalents decreased by $3.9 million during the quarter.
• The company's operating expenses increased slightly.

Risks

• The company faces risks related to economic conditions, product demand, and market acceptance.
• There are risks associated with supply chain inputs, including labor, raw materials, and transportation costs.
• Uncertainty in government funding and support for key programs poses a risk.
• The company faces competition in winning new contracts.
• Technological difficulties and potential legal claims arising from such difficulties are a risk.
• The company's ability to meet technological development milestones and overcome development challenges is a risk.

Future Outlook

The company is focused on commercializing its mass spectrometry technology through its subsidiaries and is working towards TSA certification for its TRACER 1000 product. The company is also exploring new applications for its technology.

Management Comments

• Management believes the AgLAB 1000-D2 will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for distillation processors of hemp and cannabis.
• Management believes the company is the only provider of a mass spectrometry system that gives it a distinct advantage in the industry.
• Management does not believe any legal matters will have a material adverse effect on the company's financial position or results of operations.

Industry Context

The company operates in the mass spectrometry market, which has applications in security, agriculture, healthcare, and industrial process control. The company is competing with traditional technologies in these markets and is seeking to differentiate itself through its proprietary AMS Technology.

Comparison to Industry Standards

• The company's TRACER 1000 competes with ion mobility spectrometry (IMS)-based ETDs, which the company believes have issues with false positives and limited threat detection libraries.
• The company's AgLAB 1000-D2 competes in the hemp and cannabis market, where there is a growing demand for process optimization and quality control.
• The company's BreathTech is developing a breath analysis tool to screen for VOC metabolites, which is a growing area of interest in healthcare.
• The company's Pro-Control is focused on industrial process control applications, where there is a need for real-time monitoring and control of manufacturing processes.

Stakeholder Impact

• Shareholders will be negatively impacted by the increased net loss and decreased revenue.
• Employees may be impacted by the company's financial performance.
• Customers may be impacted by the company's ability to deliver products and services.
• Suppliers may be impacted by the company's financial performance.
• Creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue field trials with the TSA for the TRACER 1000.
• AgLAB will continue sales efforts for the AgLAB 1000-D2.
• The company will continue to explore new applications for its AMS Technology.

Key Dates

Keywords

mass spectrometry, explosives detection, narcotics detection, cannabis, hemp, breath analysis, industrial process control, TRACER 1000, AgLAB 1000, BreathTest-1000, Pro-Control 1000, TSA, ECAC